Demodex Blepharitis in Scleral Lens Wearers
Sponsor: Boston Sight • ClinicalTrials.gov ID: NCT07561450
Recruiting for Similar Conditions?
Sponsors are looking for patients like you. See if you qualify for compensated research studies.
Check Eligibility →Description
The purpose of this study will be to see if Xdemvy (lotilaner ophthalmic solution) 0.25% has a positive impact on ocular surface symptoms and PROSE device functionality and performance. The investigators hypothesize the use of Xdemvy in subjects utilizing PROSE treatment will be well tolerated and that the reduction in Demodex mite load on the eyelid margin will result in reduced ocular surface symptoms and improved PROSE tolerance and functionality.
Interventions
-
Xdemvy
(Drug)
All subjects enrolled inthis study will be treated with xdemvy
Eligibility criteria
Conditions
Locations
- BostonSight — Needham, Massachusetts, United States
Partner with Nurenyx
Showcase your study to thousands of motivated patients matching your criteria.
Learn MoreOfficial Source
Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
View Official Record